Martin Misch

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial

Ulrich Herrlinger, Theophilos Tzaridis, Frederic Mack et al. · The Lancet · 2019 · 556 citations · Full text

Hematological Malignancy, Neuro-oncology, Treatment Strategies +13

A vaccine targeting mutant IDH1 in newly diagnosed glioma

Michael Platten, Lukas Bunse, Antje Wick et al. · Nature · 2021 · 400 citations · Full text

Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection

Florian Ringel, Haiko Pape, Michael Sabel et al. · Neuro-Oncology · 2015 · 255 citations · Full text

IDH1/2 mutations in WHO grade II astrocytomas associated with localization and seizure as the initial symptom

Florian Stockhammer, Martin Misch, Hans-Joachim Helms et al. · Seizure · 2012 · 143 citations · Full text

Neuro-oncology, Idh1/2 Mutations, Neurological Disorder +10

The genomic and transcriptional landscape of primary central nervous system lymphoma

Josefine Radke, Naveed Ishaque, Randi Koll et al. · Nature Communications · 2022 · 133 citations · Full text